News

NBRI establishes advanced virology lab for COVID-19 testing at Lucknow

It is a Bio Safety Level (BSL) 3 level facility and has been developed based on the guidelines of the Indian Council Medical Research (ICMR), the World Health Organisation (WHO), and the Ministry of Health and Family Welfare.

Read More

Jul 01, 2020

By : Team ABLE

Hetero starts supply of Covifor, its Remdesivir generic drug for COVID-19 treatment

ABLE member company, Hetero Drugs, through its subsidiary Hetero Healthcare Ltd, has started supply initial batch of 20,000 vials of Covifor, the Remdesivir generic version made under license from American company, Gilead Sciences

Read More

Jul 01, 2020

By : Team ABLE

Eco-friendly Synthesis of Gold Nanoparticles from Antarctic Bacteria for Therapeutic Use

Through a study, NCPOR and GU have established that 20-30-nm-sized spherical-shaped GNPs could be synthesized in a controlled environment.

Read More

Jun 30, 2020

By : Team ABLE

RevImmune initiates Phase II trial of the T-Cell Growth Factor CYT107 for COVID-19

Therapy with CYT107 is designed to substantially increase the number of immune T cells and correct the immune exhaustion.

Read More

Jun 30, 2020

By : Team ABLE

Cipla and Boehringer Ingelheim to co-market three oral anti-diabetic drugs

Cipla and Boehringer Ingelheim have partnered in India to co-market three new oral anti-diabetics drugs Oboravo, Oboravo Met and Tiptengio.

Read More

Jun 30, 2020

By : Team ABLE

 

BioEconomy Conclave 2026

24th February | TAJ MG Road, Bengaluru

Exhibit in the 'India Pavilion' at BIO 2026

June 22-25 | San Diego, USA

Focus Areas

Highlights